O'Rourke & Company, Inc Arrowhead Pharmaceuticals, Inc. Transaction History

O'Rourke & Company, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$26.2 - $36.08 $25,178 - $34,672	-961 Reduced 10.89%	7,860 $211,000
Q2 2023 Jul 25, 2023	SELL	$25.16 - $41.38 $4,025 - $6,620	-160 Reduced 1.78%	8,821 $315,000
Q1 2023 May 12, 2023	SELL	$23.68 - $38.51 $118 - $192	-5 Reduced 0.06%	8,981 $228,000
Q4 2022 Feb 13, 2023	SELL	$28.0 - $40.56 $12,376 - $17,927	-442 Reduced 4.69%	8,986 $364,000
Q2 2022 Aug 12, 2022	SELL	$27.79 - $50.61 $1,667 - $3,036	-60 Reduced 0.63%	9,428 $332,000
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $1,188 - $2,099	-30 Reduced 0.32%	9,488 $436,000
Q4 2021 Feb 16, 2022	BUY	$58.09 - $82.51 $552,900 - $785,330	9,518 New	9,518 $631,000

295

92.3M

1.33M

549K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of O'Rourke & Company, Inc, based on Form 13F filings with the SEC.

Stay updated on O'Rourke & Company, Inc with notifications on news.